Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography

Sid Gilman, Robert A. Koeppe, Larry Junck, Karen J. Kluin, Mary Lohman, Roy T St Laurent

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We used positron emission tomography with [11C]flumazenil to study gamma-aminobutyric acid type A/benzodiazepine receptor binding quantitatively in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem of 72 subjects, including 14 with multiple system atrophy of the ataxic (olivopontocerebellar atrophy) type, 5 with multiple system atrophy of the extrapyramidal/autonomic (Shy-Drager syndrome) type, 18 with sporadic olivopontocerebellar atrophy, 15 with dominantly inherited olivopontocerebellar atrophy, and 20 normal control subjects with similar age and sex distributions. In comparison with data obtained from the normal control subjects, we found significantly decreased ligand influx in the cerebellum and brainstem of multiple system atrophy patients of the olivopontocerebellar atrophy type and in patients with sporadic olivopontocerebellar atrophy, but not in patients with multiple system atrophy of the Shy-Drager syndrome type. Despite these differences in ligand influx, benzodiazepine binding was largely preserved in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem in patients with multiple system atrophy of both types as well as those with sporadic or dominantly inherited olivopontocerebellar atrophy as compared with normal control subjects. The finding of relative preservation of benzodiazepine receptors indicates that these sites are available for pharmacological therapy in these disorders.

Original languageEnglish (US)
Pages (from-to)176-185
Number of pages10
JournalAnnals of Neurology
Volume38
Issue number2
StatePublished - Aug 1995

Fingerprint

Olivopontocerebellar Atrophies
Multiple System Atrophy
GABA-A Receptors
Positron-Emission Tomography
Shy-Drager Syndrome
Cerebellum
Brain Stem
Cerebrum
Basal Ganglia
Thalamus
Ligands
Flumazenil
Sex Distribution
Age Distribution
Benzodiazepines
gamma-Aminobutyric Acid
Pharmacology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. / Gilman, Sid; Koeppe, Robert A.; Junck, Larry; Kluin, Karen J.; Lohman, Mary; St Laurent, Roy T.

In: Annals of Neurology, Vol. 38, No. 2, 08.1995, p. 176-185.

Research output: Contribution to journalArticle

Gilman, S, Koeppe, RA, Junck, L, Kluin, KJ, Lohman, M & St Laurent, RT 1995, 'Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography', Annals of Neurology, vol. 38, no. 2, pp. 176-185.
Gilman, Sid ; Koeppe, Robert A. ; Junck, Larry ; Kluin, Karen J. ; Lohman, Mary ; St Laurent, Roy T. / Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. In: Annals of Neurology. 1995 ; Vol. 38, No. 2. pp. 176-185.
@article{27bf98df674b4311b7486e7a2d11f1bb,
title = "Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography",
abstract = "We used positron emission tomography with [11C]flumazenil to study gamma-aminobutyric acid type A/benzodiazepine receptor binding quantitatively in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem of 72 subjects, including 14 with multiple system atrophy of the ataxic (olivopontocerebellar atrophy) type, 5 with multiple system atrophy of the extrapyramidal/autonomic (Shy-Drager syndrome) type, 18 with sporadic olivopontocerebellar atrophy, 15 with dominantly inherited olivopontocerebellar atrophy, and 20 normal control subjects with similar age and sex distributions. In comparison with data obtained from the normal control subjects, we found significantly decreased ligand influx in the cerebellum and brainstem of multiple system atrophy patients of the olivopontocerebellar atrophy type and in patients with sporadic olivopontocerebellar atrophy, but not in patients with multiple system atrophy of the Shy-Drager syndrome type. Despite these differences in ligand influx, benzodiazepine binding was largely preserved in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem in patients with multiple system atrophy of both types as well as those with sporadic or dominantly inherited olivopontocerebellar atrophy as compared with normal control subjects. The finding of relative preservation of benzodiazepine receptors indicates that these sites are available for pharmacological therapy in these disorders.",
author = "Sid Gilman and Koeppe, {Robert A.} and Larry Junck and Kluin, {Karen J.} and Mary Lohman and {St Laurent}, {Roy T}",
year = "1995",
month = "8",
language = "English (US)",
volume = "38",
pages = "176--185",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography

AU - Gilman, Sid

AU - Koeppe, Robert A.

AU - Junck, Larry

AU - Kluin, Karen J.

AU - Lohman, Mary

AU - St Laurent, Roy T

PY - 1995/8

Y1 - 1995/8

N2 - We used positron emission tomography with [11C]flumazenil to study gamma-aminobutyric acid type A/benzodiazepine receptor binding quantitatively in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem of 72 subjects, including 14 with multiple system atrophy of the ataxic (olivopontocerebellar atrophy) type, 5 with multiple system atrophy of the extrapyramidal/autonomic (Shy-Drager syndrome) type, 18 with sporadic olivopontocerebellar atrophy, 15 with dominantly inherited olivopontocerebellar atrophy, and 20 normal control subjects with similar age and sex distributions. In comparison with data obtained from the normal control subjects, we found significantly decreased ligand influx in the cerebellum and brainstem of multiple system atrophy patients of the olivopontocerebellar atrophy type and in patients with sporadic olivopontocerebellar atrophy, but not in patients with multiple system atrophy of the Shy-Drager syndrome type. Despite these differences in ligand influx, benzodiazepine binding was largely preserved in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem in patients with multiple system atrophy of both types as well as those with sporadic or dominantly inherited olivopontocerebellar atrophy as compared with normal control subjects. The finding of relative preservation of benzodiazepine receptors indicates that these sites are available for pharmacological therapy in these disorders.

AB - We used positron emission tomography with [11C]flumazenil to study gamma-aminobutyric acid type A/benzodiazepine receptor binding quantitatively in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem of 72 subjects, including 14 with multiple system atrophy of the ataxic (olivopontocerebellar atrophy) type, 5 with multiple system atrophy of the extrapyramidal/autonomic (Shy-Drager syndrome) type, 18 with sporadic olivopontocerebellar atrophy, 15 with dominantly inherited olivopontocerebellar atrophy, and 20 normal control subjects with similar age and sex distributions. In comparison with data obtained from the normal control subjects, we found significantly decreased ligand influx in the cerebellum and brainstem of multiple system atrophy patients of the olivopontocerebellar atrophy type and in patients with sporadic olivopontocerebellar atrophy, but not in patients with multiple system atrophy of the Shy-Drager syndrome type. Despite these differences in ligand influx, benzodiazepine binding was largely preserved in the cerebral hemispheres, basal ganglia, thalamus, cerebellum, and brainstem in patients with multiple system atrophy of both types as well as those with sporadic or dominantly inherited olivopontocerebellar atrophy as compared with normal control subjects. The finding of relative preservation of benzodiazepine receptors indicates that these sites are available for pharmacological therapy in these disorders.

UR - http://www.scopus.com/inward/record.url?scp=0029091201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029091201&partnerID=8YFLogxK

M3 - Article

C2 - 7654065

AN - SCOPUS:0029091201

VL - 38

SP - 176

EP - 185

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -